What is Stereotaxis?
Stereotaxis (NYSE: STXS) is at the forefront of developing and delivering robotic systems, instruments, and information solutions for the interventional laboratory. Their innovative technology aims to empower physicians with enhanced patient care through robotic precision and safety, expanding access to minimally invasive therapies, and improving the overall productivity and connectivity within surgical environments. The company's focus on interventional cardiology and neurosurgery positions it as a key player in the rapidly evolving field of medical robotics.
How much funding has Stereotaxis raised?
Stereotaxis has raised a total of $497.1M across 23 funding rounds:
Stock Offering
$10.2M
Debt
$10M
Share Placement
$24M
Other Financing Round
$10M
Share Placement
$25M
Debt
$2M
Share Placement
$15M
Other Financing Round
$50M
Stock Issuance/Offering (2013): $10.2M with participation from Undisclosed
Debt (2014): $10M led by Silicon Valley Bank
Share Placement (2016): $24M supported by Joe Kiani and DAFNA Capital Management
Other Financing Round (2018): $10M featuring Undisclosed
Share Placement (2019): $25M backed by Redmile Group, Opaleye Management, and Parkman Healthcare Partners
Debt (2020): $2M with participation from PPP
Share Placement (2020): $15M led by Consonance Capital Management
Other Financing Round (2025): $50M supported by Roth Capital Partners
Key Investors in Stereotaxis
Advent International
Advent International is a leading global private equity firm specializing in buyouts and growth equity across various sectors, including healthcare. Their investment in Stereotaxis likely indicates a strategic focus on expanding the company's market presence and technological capabilities.
Ascension Ventures
Ascension Ventures is a strategic healthcare venture firm backed by major health systems. Their participation suggests a belief in Stereotaxis's ability to transform healthcare delivery and improve patient outcomes through advanced robotic solutions.
CID Equity Partners
CID Capital is a private equity group focused on control investments in lower middle market companies. Their involvement points to a strategic interest in Stereotaxis's established market position and potential for further growth and operational enhancement.
What's next for Stereotaxis?
The recent major strategic investment in Stereotaxis suggests a strong market confidence in the company's future trajectory and its potential to further innovate within the surgical robotics sector. This influx of capital is likely to fuel research and development, expand market reach, and potentially support strategic acquisitions or partnerships. As the demand for minimally invasive procedures continues to grow, Stereotaxis is well-positioned to leverage this financing to solidify its leadership and drive the next generation of robotic-assisted surgery.
See full Stereotaxis company page
